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Natural infections expose the immune system to escalating antigen
and inflammation over days to weeks, whereas nonlive vaccines are
single bolus events. We explored whether the immune system
responds optimally to antigen kinetics most similar to replicating
infections, rather than a bolus dose. Using HIV antigens, we found
that administering a given total dose of antigen and adjuvant over
1–2 wk through repeated injections or osmotic pumps enhanced
humoral responses, with exponentially increasing (exp-inc) dosing
profiles eliciting >10-fold increases in antibody production relative
to bolus vaccination post prime. Computational modeling of the ger-
minal center response suggested that antigen availability as higher-
affinity antibodies evolve enhances antigen capture in lymph nodes.
Consistent with these predictions, we found that exp-inc dosing led
to prolonged antigen retention in lymph nodes and increased Tfh cell
and germinal center B-cell numbers. Thus, regulating the antigen and
adjuvant kinetics may enable increased vaccine potency.
vaccination kinetics | antigen retention | humoral response |
computational immunology | germinal center formation
Subunit vaccines based on recombinant protein antigenscombined with adjuvants can safely elicit protective humoral
immune responses in humans, and they have become a corner-
stone of modern public health (1, 2). Recent advances in struc-
ture-based vaccine design (3, 4) and progress in the development
of adjuvants that are safe and effective for prophylactic vaccines
(5) have helped drive the field. However, several challenges re-
main: A number of protein vaccines, such as candidate vaccines
against HIV and malaria, have tended to elicit short-lived im-
munity (6, 7). In HIV, broadly neutralizing antibodies (BNAbs)
isolated from infected patients are generally characterized by high
degrees of somatic hypermutation (SHM) (8), but methods to
generate such highly mutated antibodies by vaccination remain
unknown. SHM occurs in germinal centers (GCs) within lymphoid
organs, and data from animal models demonstrate a critical role
for follicular helper T cells in the induction of GCs and promotion
of affinity maturation (9, 10). To date, methods to promote Tfh
generation and long-lived germinal centers during vaccination
remain unclear (11–15). Much attention has focused on the use of
adjuvants to promote affinity maturation, but it remains unclear if
adjuvants alone can provide the necessary immunological driving
forces for promoting extensive affinity maturation (16).
During acute infections, which often provoke robust germinal
center responses and durable humoral immunity, microorganism
replication typically occurs over the course of one to several
weeks (17–19). During this time, recognition of molecular danger
signals contained within the pathogen sustains stimulation of the
innate immune system, and a continuous supply of antigen is
provided to the adaptive immune system. In contrast to these
patterns of antigen and inflammatory cues during infection,
typical subunit vaccines show much more rapid clearance fol-
lowing injection. During a primary immune response, parenter-
ally injected proteins are detected in lymph nodes within minutes
to a few hours but are largely flushed away within 1–2 d (12, 20).
Adjuvants such as alum and MF59 are believed to act as antigen
depots altering these kinetics, but biodistribution studies suggest
that clearance of antigen from injection sites and lymph nodes is
often nearly indistinguishable for soluble vs. alum-adsorbed or
MF59-adjuvanted antigens (21–23). As such, the effect of sub-
unit vaccine kinetics on the humoral immune response remains
poorly understood. Given that germinal centers peak multiple
weeks after antigen exposure, it is reasonable to postulate that
antigen kinetics may have a profound effect on the magnitude
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and quality of the germinal center response and long-term humoral
immunity.
Here we explored the effects of systematically varied temporal
dosing patterns on the humoral immune response to model HIV
subunit vaccines consisting of recombinant CD4 binding site-
presenting gp120 monomer (24, 25) or SOSIP native-like HIV
Env trimer proteins (26–28). We find that certain extended-
duration dosing profiles increased the strength of the humoral
response, with exponentially increasing patterns providing the
greatest enhancement. Guided by a computational model of the
effects of vaccine kinetics on the germinal center response, we
found that exponentially increasing dosing kinetics promoted
capture and retention of the antigen in lymph nodes, leading to
increased germinal center B-cell expansion, plasma cell genera-
tion, and Tfh cell numbers.
Results
Exponentially Increasing Dosing Profiles During Priming Durably
Increase the Production of Antigen-Specific IgG. We hypothesized
that extended exposure to antigen and adjuvant, better mim-
icking the kinetics of live infections, would augment the response
to vaccination. As a model vaccine, we used a previously de-
scribed gp120 stripped core antigen containing the CD4 binding
site (24, 25), which was mixed with monophosphoryl lipid A
(MPLA) as a clinically relevant adjuvant (29). We first evaluated
the effect of altering vaccination kinetics by extending the dosing
of the prime over 1 wk. Groups of mice were immunized with
either a conventional bolus injection on day 0 or seven daily
injections over 1 wk testing three concepts: exponentially in-
creasing (exp-inc), exponentially decreasing (exp-dec), or
constant dosing, where the summed total dose of antigen and
adjuvant was kept the same in all groups (Fig. 1A and Table S1).
All groups received a boost as a single bolus injection at day 21.
Following priming, exp-inc and constant dosing profiles elicited
strikingly higher IgG responses by day 14 compared with bolus
immunization, with anti-gp120 Ab concentrations 14-fold and
∼8-fold higher (P < 0.001), respectively, than bolus injection at
day 14, roughly equivalent to the titers achieved by traditional
bolus immunization after the boost (Fig. 1 B and C). By contrast,
an exp-dec dosing pattern elicited titers postprime that were
indistinguishable from the bolus control. Following the boost
administered at day 21, animals that received an exp-inc prime
continued to show higher anti-gp120 Ab levels, which were 2.7
times greater (average over time) than the bolus-primed group
(Fig. 1C; P < 0.001). This effect was durable, lasting 150 d. By
contrast, the constant-dosing prime elicited Ab levels only 1.6
times higher than bolus injection (P = 0.040), and the exp-dec
prime was not significantly different from bolus prime. Thus,
certain extended vaccine kinetic profiles, especially in an in-
creasing dosing pattern, enhanced the long-term concentration
of antigen-specific IgG produced.
Extended Dosing Profiles over 2 wk Maximize Antibody Titers. We
hypothesized that dosing over a 1-wk period may be suboptimal,
given the more prolonged kinetics of germinal centers and the
kinetics of many acute infections. As exp-inc dosing resulted in
elevated antibody titers, we next tested how the duration of this
dosing pattern influenced the humoral response. We compared
exp-inc dosing profiles administered over 7, 14, or 21 d, keeping
the total number of injections (7) and total dose constant. For
each pattern, the bolus boost was given 14 d after the last
priming injection (Fig. 2A and Fig. S1A). To account for the
effect of a later boost, we also introduced a second control with
single-dose prime and a boost at day 28. As seen in Fig. 2B,
extending the dosing course from 7 to 14 d increased the mag-
nitude of the antibody response, with the 2-wk exp-inc dosing
pattern eliciting ∼48-fold higher concentrations of gp120-specific
antibodies than the corresponding bolus prime group by day 21
(P < 0.001; Fig. 2B). Further extending the exp-inc dosing profile
from 14 to 21 d led to a slightly weaker humoral response than
the 2-wk profile (Fig. S1). Postboost, 1- and 2-wk exp-inc dosing
elicited sustained gp120-specific IgG levels that were 3.6-fold
(P < 0.001) and 6.6-fold higher (P < 0.001) than their equiva-
lently timed bolus prime/boost controls (Fig. 2C).
To determine the relative importance of an increasing dosing
profile on the prime vs. boost response, we compared exp-inc
dosing profiles administered only during the prime, only during
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Fig. 1. Exponentially increasing dosing schedules during priming durably increase antigen-specific IgG production relative to traditional bolus immunization.
Groups of C57BL/6 mice (n = 5 per group) were immunized with 5 μg gp120 mixed with 25 μg MPLA according to the dosing schedules shown in A, followed
by a single bolus booster injection of 5 μg gp120 + 25 μg MPLA on day 21. (B) Fold change in antibody concentration on day 14 postprime relative to bolus
injection. *P < 0.05; ***P < 0.0001 compared with bolus injection determined by ANOVA with Dunnett’s test post hoc using bolus injection as the control.
Shown are means ± SEM. (C) Total serum anti-gp120 IgG as measured by ELISA. Asterisk indicates statistically different from boost d21 group as determined
by two-way ANOVA with Dunnett’s post hoc test using bolus injection as the control. Data are representative of two independent experiments.
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Fig. 2. Exponentially increasing dosing profiles extended over 2 wk with an exponentially increasing boost enhance the humoral response. Groups of
C57BL/6 mice were immunized with 5 μg gp120 + 25 μg MPLA following the dosing schedules shown in A and D. (B) Fold change in antibody concentration
on day 21 postprime relative to bolus injection. p was determined by unpaired Mann–Whitney test. (C) Total serum anti-gp120 IgG (n = 10 per group) as
measured by ELISA. Asterisk indicates statistically different from boost d21 group as determined by two-way ANOVA with Dunnett’s post hoc test using
bolus injection as the control. (E ) Fold change in antibody concentration on day 49 (postboost) relative to bolus injection. *P < 0.05 determined by
Kruskal–Wallis test with Dunn’s multiple comparison’s test. (F ) Total serum IgG (n = 5 per group) measured by ELISA. Asterisk indicates statistically
different from boost d21 group as determined by two-way ANOVA with Dunnett’s post hoc test using bolus injection as the control. (G) Mice were
immunized either with gp120 plus MPLA following schedules shown in D or with gp120 formulated in 100 μg alum (aluminum phosphate, prime day 0,
boost day 28). Serum was collected at day 49, and anti-gp120 isotype titers were analyzed by ELISA. Asterisk indicates statistically different from boost d28
group as determined by two-way ANOVA with Dunnett’s post hoc test using bolus injection as the control. (H) ELISA for binding to gp120 for day 49 sera
was performed in the presence of competing broadly neutralizing antibody VRC01. Shown is ELISA optical density as a percentage of uncompeted signal.
p was calculated by unpaired Mann–Whitney test. All values shown are mean ± SEM. Data are representative of experiments done twice (A–C ) or once
(D–H), using at least five mice per group.
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the boost, or during both prime and boost (Fig. 2D). Incor-
poration of an exp-inc dosing profile for both the prime and
boost resulted in significantly higher serum Ab concentrations
than either exp-inc prime/bolus boost or bolus prime/exp-inc
boost regimens (Fig. 2 E and F). To evaluate the effect of ex-
tended dosing on class switching, we analyzed titers of different
Ab isotypes induced. Exp-inc dosing substantially increased the
titers of multiple Ig isotypes, including IgG1, IgG3, and IgG2a
that was near background following traditional bolus immuni-
zation (Fig. 2G). We also compared exp-inc vaccination to tra-
ditional bolus vaccination using alum as the most common
clinical adjuvant, which has been proposed to provide a depot
effect with some antigens (30). As shown in Fig. S2, alum pro-
vided comparable antibody responses to bolus vaccination using
MPLA as adjuvant (P = 0.88), but was much inferior to exp-inc
dosing of the vaccine, and also elicited almost exclusively IgG1
titers (P = 0.038; Fig. 2G). Finally, we tested the capacity of
vaccine-elicited antibodies to compete with the BNAb VRC01
for binding to the gp120 antigen by ELISA; exp-inc vaccine
dosing increased the proportion of antibodies induced that
blocked VRC01 binding (Fig. 2H). Altogether, these results in-
dicate that for a given total quantity of antigen and adjuvant,
extended vaccine kinetics obtained by administering the vaccine
over at least 2 wk in increasing doses is capable of durably in-
creasing total output serum concentrations of elicited antigen-
specific IgG by more than sevenfold, elevating the production of
multiple isotypes of Ab.
A Computational Model of the Germinal Center Response Predicts
Antibody-Based Feedback Governs the Response to Extended
Dosing Vaccines. In a traditional bolus immunization, the half-
life of the antigen present in lymph nodes is shorter than the time
scale over which GC reactions start producing higher affinity IgG
antibodies relative to the initial IgM response (12, 20). Thus,
most antigen displayed on follicular dendritic cells (FDCs) is in
the form of immune complexes (IC) of antigen with weakly
bound IgM antibodies (31, 32); this may lead to a suboptimal
level of antigen concentration on FDCs. We hypothesized that
extended vaccine dosing may better match the time scale of
antigen availability to the kinetics of the GC reaction compared
with bolus immunization, leading to more ICs formed with newly
evolved higher-affinity antibodies, thereby promoting more
prolonged retention on FDCs. To explore whether this feedback
mechanism alone can account for the significant effect of ex-
tended dosing profiles observed experimentally, we constructed a
coarse-grained computational model with a minimal number of
parameters. The goal of the model was to test whether our hy-
pothesis could provide an explanation for the data and, if so, to
subject it to experimental tests. The model particularly focuses
on antigen transport, the GC reaction, and antibody production
by plasma cells in a lymph node (Fig. 3A). It makes the following
assumptions: (i) As a simplified approximation of experimental
observations of soluble antigen transport following injection, we
assume that antigen arrives at the lymph node immediately fol-
lowing immunization, and free antigen in the lymph node clears
exponentially over time with a half-life of ∼17 h (20, 33). Natural
IgM initiates the immune response and captures antigen arriving
in the lymph node with a low affinity (32). (ii) B cells class-switch
only to IgG and not to other Ig subclasses after the GC reaction
ensues. (iii) The onset of IgG production occurs 6 d after the
initial antigen injection, reflecting the observation that it takes a
few days for GC reactions to occur before class switching ini-
tiates (34, 35). (iv) The GC B-cell population size is assumed to
be constant during the GC reaction. Although this is incorrect,
qualitative results emerging from models of evolutionary pro-
cesses that make this approximation are often accurate (36).
(v) The formation of ICs is the rate-limiting step in antigen pre-
sentation to GC B cells; that is, the model assumes that transport
0 5 10 15
0
10
20
30
40
Days
C
on
ce
nt
ra
tio
n 
(n
M
) Exp-inc
0 5 10 15
0
5
10
15
Days
Constant
0 5 10 15
0
5
10
15
20
Days
Exp-dec
0 5 10 15
0
5
10
15
20
25
Days
Bolus
IgM
IgG
Ag
Plasma B cell
GC B cell
IgG production
Enhanced
 IC formation
Greater IC retention
Apoptosis
Selection
Expansion
SHM
A
1. Initial IC formation:
 CAg + CIgM    CIc
2. Coarse-grained GCRs:
 CIC + CB CPC
3. IgG production by plasma B cells (t > 6 days):
 CPC       CAb + CPC
4. Enhanced IC formation (t > 6 days):
 CAg + CIgG    CIC 
β1
β2(t)
k
β2(t)
B
C
D
0 5 10 15
0
10
20
30
40
C
on
ce
nt
ra
tio
n 
(n
M
) IC
0 5 10 15
0.1
1
10
100
1000
Days
C
on
ce
nt
ra
tio
n 
(n
M
) IgG
0 5 10 15
0
10
20
30
40
Total antigen in Lymph node 
Days
C
on
ce
nt
ra
tio
n 
(n
M
)
Exp-inc
Exp-dec
Constant
Bolus
0 5 10 15
0.00
0.05
0.10
C
on
ce
nt
ra
tio
n 
(n
M
) IgM
0 5 10 15
101
102
103
104
105 Plasma Cells
N
um
be
r o
f C
el
ls
Fig. 3. A computational model of the germinal center response predicts enhanced immune complex formation and IgG production by extended-dosing/
increasing vaccination profiles. (A) Schematic of components of antigen transport, GC reaction, and antibody production model. (B) Four reactions of the
model including antigen capture by ICs at initial and later stages of the immune response, coarse-grained germinal center reaction, and antibody production.
CB, concentration of germinal center B cells; CAg, concentration of free Ag; CIC, concentration of ICs; CIgM, concentration of IgM; CIgG, concentration of IgG;
CPC, concentration of plasma cells. (C) Kinetic profile of free antigen in lymph nodes predicted by the model with fitted k (2.56 × 10
6 antibodies per plasma cell
per day). (D) Kinetic profiles of IC, IgM, IgG, plasma cells, and total antigen in lymph node (free Ag + IC) predicted by the model. See also Germinal Center
Model Calculations in Materials and Methods and Table S3 for mathematical representation of the model.
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of immune complexes to FDCs is relatively fast. (vi) Ten percent
of selected B cells differentiate to plasma cells (24). (vii) IgG
affinity evolves linearly and increases by 100-fold by the end of
the GC reaction (24). Based on these assumptions, four key
reactions summarize the model (Fig. 3B). During the early phase of
the immune response, free antigen is captured by IgM at a slow
rate (proxy for affinity), β1 (Reaction 1). B cells bind to ICs in GCs
with an increasing rate β2 (proxy for affinity) as a function of time
and become plasma cells (Reaction 2), which ultimately leads to
production of IgG (Reaction 3). Because this is a coarse-grained
model, we consider only the average affinity of IgGs, although in
reality, there is a heterogeneous distribution. Plasma cells derived
from the GC reaction produce antibodies at a rate k (Reaction 3),
and the resulting higher-affinity antibodies capture antigen (Re-
action 4) at a rate β2. Parameter values were taken from the lit-
erature (Table S2) when available, except for k, which is the
number of antibodies produced by each plasma cell per day.
Nonlinear regression fitting of the model antibody output to IgG
concentrations measured experimentally at days 7 and 14 following
gp120 immunizations was performed to determine the best value of
k. This yielded a value for k of 2.56 × 106 antibodies per plasma cell
per day, which in rough agreement with the reported rate of ∼107
IgG molecules secreted by a single plasma cell per day (37).
Using these parameters, we modeled the GC reaction, im-
mune complex formation, and IgG production for each of the
1-wk vaccine dosing schedules studied experimentally in Fig. 1
(Fig. 3C). As shown in Fig. 3D, the model predicts that the hi-
erarchy of antibody production among the different dosing
schemes mirrors the hierarchy of IC concentrations. Exp-inc
dosing produces the highest level of immune complex formation
and thus the highest level of antibody output. The exp-inc dosing
profile also leads to increased GC activity and increased num-
bers of plasma cells. By contrast, the calculations suggest that IC
accumulation using the exp-dec dosing scheme is very low and
similar to that from a bolus immunization (Fig. 3D), consistent
with the experimental finding that antibody production in these
two cases was similar. A key prediction of the model is that total
antigen in lymph nodes quickly decays 24 h after the bolus im-
munization, whereas antigen is retained at high levels for many
days at the end of the exp-inc dosing schedule (Fig. 3D). Thus, a
simple model of the GC reaction focused on the effect of early
antibody evolution on antigen capture in ICs reproduces the
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Fig. 4. Exponentially increasing vaccine dosing leads to enhanced antigen capture and retention in draining lymph nodes. Groups of albino C57BL/6 mice
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(A) Dosing and sampling profiles used in this experiment. (B) Fluorescence detected from lymph nodes ex vivo (n = 4 per group) at 24 or 72 h post-last in-
jection. P value was calculated by unpaired Mann–Whitney test. Data are representative of two independent experiments. (C) Groups of C57BL/6 mice (n = 2
per group) were vaccinated with 5 μg phycoerythrin and 25 μg MPLA by bolus or exp-inc dosing following the schedule in A, followed by collection of lymph
nodes for imaging at 72 h after bolus or after last injection of 2 wk exp-inc dosing. FDC networks were labeled in situ by i.p. injection of anti-CD21/35 antibody
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qualitative results seen in our experiments and suggests that a
key mechanism of action is enhanced capture/retention of anti-
gen in lymph nodes in the exp-inc dosing profiles.
Exponentially Increasing Dosing Results in Prolonged Antigen Retention
in Lymph Nodes and Enhanced Germinal Center Formation. Motivated
by the modeling predictions, we performed a series of experiments
using infrared dye-labeled gp120 to track the amount of antigen
retained in draining lymph nodes over time and evaluated GC
induction following priming with bolus immunization or exponen-
tially increasing dosing. Groups of mice were immunized with la-
beled gp120 and MPLA, then serially killed to recover tissues for
digestion and quantification of total gp120 fluorescence in the
draining inguinal LNs at selected time points. Lymph nodes were
analyzed at 24 and 72 h following bolus injection or 24 and 72 h
after the final injection in a 2-wk exp-inc dosing regimen (Fig. 4A).
Following bolus immunization, antigen was detected in the LNs at
24 h but quickly decayed thereafter (Fig. 4B). By contrast, at the
end of the exp-inc dosing regimen, antigen remained at high, ap-
proximately constant levels for at least 3 d. To determine the an-
atomical localization of retained antigen, we repeated this
experiment using phycoerythrin (PE) as an intrinsically fluorescent
model protein antigen, vaccinating with a bolus or exp-inc dosing
regimen. Twenty-four hours after bolus immunization, little or no
antigen could be detected on FDCs or any other location in lymph
nodes, whereas 24 h after the final injection in the exp-inc regimen,
substantial amounts of PE were detected lining the FDC network
(Fig. 4C). Thus, exp-inc dosing enhanced antigen retention in
lymph nodes at the end of the injection schedule compared with
bolus vaccination, with preferential retention on FDCs, as pre-
dicted by the computational model of the GC reaction.
We next analyzed B-cell populations in the draining inguinal
lymph nodes of mice receiving bolus vs. 2-wk exp-inc vaccine
dosing regimens (Fig. 5A). Germinal center B cells were tracked
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Fig. 5. Exponentially increasing vaccine dosing promotes germinal center B-cell differentiation. C57BL/6 mice were immunized with either 5 μg gp120 and
25 μg MPLA, MPLA only, or gp120 only, following the dosing schemes depicted in A. (B) Lymph node sections were stained for B cells (B220; blue) and GL7 (pink)
and analyzed by confocal microscopy. (Magnification: 10×.) (C–E) Draining LNs were collected at the indicated time points, and cell suspensions were analyzed
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Representative flow cytometry plots (Left) and cell counts (Right) are shown. *P < 0.05, **P < 0.01, and ***P < 0.001 determined by Kruskal–Wallis test with
Dunn’s multiple comparison’s test. Error bars are SEM. Data are representative of four independent experiments.
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over time, and plasmablasts were compared by flow cytometry on
days 7 and 13 for both regimens. Significant numbers of GC B cells
did not develop following bolus immunization until day 13, and the
GCs contracted by day 21 (Fig. 5 B and C). Exp-inc–vaccinated
mice showed germinal center responses over a similar time frame,
but GC B-cell numbers escalated dramatically between days 7 and
13, reaching 3.7-fold higher peak levels of GC B cells (P = 0.040 for
2-wk exp-inc d13 vs. bolus d13; Fig. 5 B and C). Notably, expo-
nential dosing led to overall greatly increased cell numbers in
lymph nodes at these peak GC time points. Adjuvant-only and
antigen-only controls indicated that this germinal center response
was largely antigen-specific but dependent on the presence of ad-
juvant (Fig. 5C). Exp-inc vaccination also stimulated a massive
expansion of plasma cells on day 13, which was not observed at any
time point for traditional bolus immunization (P < 0.0001; Fig.
5D). B-cell activation in the draining LNs at 24 h after the final
injection of the exp-inc dosing regimen was similar to 24-h post-
bolus injection (Fig. 5E). Thus, an escalating pattern of vaccine
dosing amplified the germinal center response and altered B-cell
differentiation patterns in the lymph node.
True Continuous Antigen Exposure Elicits Increased Germinal Center
and Serum Antibody Responses. Because we experimentally pro-
longed vaccine dosing through repeated injections, a question
that remained was whether similar vaccine results would be
obtained in the setting of true continuous antigen exposure. To
answer this question, a series of experiments were performed
using mini osmotic pumps, nonmechanical delivery devices that
can release a material continuously over a specific period of
weeks in vivo when implanted s.c. Mice were immunized with
osmotic pumps containing native-like BG505 SOSIP HIV Env
trimers (26–28) admixed with an ISCOMs-type adjuvant, and
CD4+ T-cell, B-cell, and antibody responses were assessed. As
shown in Fig. 6A, we compared traditional bolus vaccination with
SOSIP trimer and ISCOMATRIX to immunizations where os-
motic pumps were implanted for release of vaccine over 1 wk or
immunizations using pumps releasing vaccine for 2 wk. Moti-
vated by our results that suggest the key feature of the escalating
dosing pattern is the availability of antigen at the end of the
dosing schedule, we administered a bolus injection at the end of
each pump lifespan (days 7 and 14 for the 1 and 2 wk pumps,
respectively) to provide a high dose of antigen at the end of the
dosing pattern. Animals in each group were boosted with the
same regimens after 9 and 20 wk. We evaluated GC B-cell and
Tfh cell numbers 4 wk after the final immunization. Sustained
immunogen delivery using the osmotic pumps increased the
frequency and absolute number of germinal center Tfh cells
(CXCR5hi PD-1hi; Fig. 6B) and overall Tfh cells (Fig. 6C) in the
draining lymph nodes. The greatest GC Tfh increase (∼three-
fold) was observed for pumps providing 2 wk of vaccine release.
Total numbers of Tfh cells (CXCR5+) measured by flow cytom-
etry were also increased by osmotic pump-based sustained vac-
cine kinetics, with 2-wk osmotic pumps eliciting the greatest
increase in total Tfh numbers compared with bolus immunizations
(Fig. 6C). Overall numbers of GC B cells were elevated ∼threefold
by the 2 wk extended dosing osmotic pump regimen (Fig. 6D),
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consistent with the knowledge that GC B-cell numbers closely
correlate with the availability of GC Tfh cells. No response was
observed in animals receiving adjuvant alone (Fig. S3).
Native-like SOSIP Env trimers generally elicit very low serum
antibody responses after primary immunization (38, 39), which is
a common feature of many protein immunogens. In contrast,
provision of immunogen by extended in vivo release elicited
significant antitrimer IgG responses after the first immunization
(Fig. 6E). These enhancements translated to a 15-fold increase in
total SOSIP-specific IgG titers in the serum after booster im-
munization (P = 0.0062; Fig. 6E). Additionally, consistent with
our previous study (39), bolus immunization led to a prepon-
derance of antibodies directed against the V3 loop not exposed
on the intact trimer, suggesting some degree of active degrada-
tion of the immunogen in vivo (Fig. 6F). These nonneutralizing
V3-specific responses were not detected in the osmotic pump-
immunized animals (Fig. 6F), demonstrating that the osmotic
pumps both provide robust immunological response benefits by
altering the antigen dose kinetics and protect the immunogen
structure. Thus, consistent with our findings from dosing pro-
files achieved by repeated injections, extended vaccine dosing
with osmotic pumps led to increased antibody titers and GC
development.
Discussion
The majority of licensed vaccines are thought to protect through
the induction of long-lived neutralizing antibody responses (40).
Methods to enhance humoral immunity and particularly to pro-
mote the germinal center reaction where antibody affinity matu-
ration occurs are of great interest for improved vaccines and may
be especially important for the development of a successful HIV
vaccine (41–43). Strategies to influence the B-cell response include
the selection of appropriate adjuvants (5), use of multiple immu-
nogens to steer antibody responses (44, 45), and control over the
dose and timing of antigen and adjuvant exposure through the
method of vaccine delivery (46). Recent unexpected findings with
HIV Env protein vaccines in nonhuman primates demonstrating
that a variety of clinically relevant adjuvants fail to promote affinity
maturation to degrees greater than injection of protein alone in-
dicate that adjuvants alone may not be capable of inducing optimal
antibody responses (16).
Here we focused on the temporal profile of vaccination and its
impact on the humoral response. Generating three basic temporal
patterns of vaccine exposure, we found that administering antigen
in increasing doses with time led to humoral responses that were
significantly greater than constant-dosing or decaying-dosing pro-
files. Exponentially increasing dosing over 2 wk at both prime and
boost durably increased antibody titers 19-fold relative to tradi-
tional bolus immunizations. A computational model suggested that
extended antigen dosing profiles lead to better antigen capture in
the germinal center because of the delayed nature of IgG IC for-
mation. These predictions were borne out by experimental analyses
demonstrating that exponentially increasing vaccine kinetics led to
prolonged antigen retention in lymph nodes and enhanced ger-
minal center induction.
A number of studies have sought to enhance immune re-
sponses through the use of controlled-release devices to sustain
vaccine exposure over prolonged periods, but these efforts have
largely focused on the notion of replacing repeated injections
with constant continuous exposure over 1 or more months, and
mechanisms underlying the response to such sustained release
formulations have not been explored (47–50). We were inspired
by the previous work of Johansen et al. (51), who demonstrated
that T-cell responses to peptide vaccination are substantially
enhanced by immunizing in an increasing dosing pattern. Here we
show that such vaccine kinetics are also highly favorable for the
antibody response, through the interplay of antibody production
and B-cell stimulation in germinal centers. The strong influence of
vaccine kinetics on the antibody response is likely an evolved
mechanism optimizing B-cell activation in the face of replicating
pathogens. Antigen load and inflammation during acute infections
follow similar kinetic patterns as the exponentially increasing dos-
ages that elicited optimal antibody titers and GC induction in these
simple protein vaccinations. Furthermore, GCs can be active for
weeks or months, and thus, it is logical that the availability of
vaccine antigen at later time points in that process can be an im-
portant limiting factor for the quantity and quality of the memory B
cells and plasma cells produced by the GCs.
Although we focused our studies here on fixed doses of antigen/
adjuvant, the total dose of the vaccine will also play an important role
in the immunization outcome; for example, too high a level of an-
tigen will cause the development of low-affinity antibodies. Although
we found that an increasing antigen dosing profile can produce
higher antibody titers, two important questions were not answered:
(i) What is the dosing kinetic scheme that also leads to high-affinity
antibodies, not just higher titers? (ii) Are there dosing kinetic
schemes that are even more efficient than the exponentially in-
creasing scheme that we studied? The possibility of an optimal dosing
profile is suggested by the fact that intermediate antigen concentra-
tions lead to the highest affinity antibodies (24) and that an optimal
dosing profile may be one that matches the kinetics of dosing with
the natural time scales of the GC reaction. Answering these ques-
tions will require that a large parameter space of dosing intervals and
kinetic patterns be explored. Future studies are also needed to de-
termine whether these profiles increase the rate of somatic hyper-
mutation, which is known to be important in HIV protection.
For widespread prophylactic vaccines meant for global distri-
bution, it is impractical to envision vaccine regimens based on a
daily series of injections, especially in the developing world
where access to healthcare system can be challenging. Thus, an
important next step for the concepts presented here will be
implementation of vaccine delivery methods that allow vaccine
exposure patterns as described here to be achieved following a
single administration. Methods that may be suitable include the
use of microneedle patches, biodegradable microparticles, or
other controlled-release devices (52–55). Such delivery systems
have been shown to be able to deliver large proteins and other
vaccine components in increasing dose profiles. They are also
well characterized and have in some cases been commercialized,
and their release kinetics are generally well understood (56, 57).
In summary, we have demonstrated that prolonged vaccine ex-
posure during germinal center induction leads to enhanced GC
B-cell differentiation and antigen-specific antibody production.
Computational modeling suggested this effect was driven by
enhanced capture of antigen in lymph nodes by evolving higher-
affinity antibodies early in the GC response, a prediction borne
out by experimental measurements of antigen retention in lymph
nodes. This work demonstrates a key role for vaccine kinetics in
the response of B cells to immunization, which may prove to be an
effective method for increasing the efficacy of subunit vaccines.
Materials and Methods
Materials. His-tagged Gp120 was expressed in HEK293 cells in serum-free
media for 1 wk, and the supernatant was purified with Talon metal affinity
chromatography resin (Clontech) followed by size-exclusion chromatography.
The plasmid used was fromMata-Fink et al. (25). BG505 SOSIP.664 trimers were
expressed in HEK293 cells expressing the SV40 large T-antigen (HEK293T) or
Chinese hamster ovary (CHO) cells and purified with a 2G12 mAb-affinity
column followed by size-exclusion chromatography as previously reported (28,
58). Poly-L-lysine hydrobromide (MW 500–2000) and monophosphoryl lipid A
(MPLA) from Salmonella enterica serotype Minnesota Re 595 were purchased
from Sigma-Aldrich. BSA (BSA; IgG-free) and HRP-conjugated goat anti-mouse
IgG, Fc fragment specific (HRP-IgG) were purchased from Jackson Immuno-
Research. IRDye 800CW-NHS was purchased from LI-COR Biosciences. HRP-
conjugated goat anti-human IgG and Fc fragment-specific (HRP-IgG) anti-human
HRP-IgG were purchased from Fisher Scientific, and 3,3′,5,5′-tetramethylbenzidine
(TMB) was purchased from eBioscience.
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Vaccination and Sample Collection. All procedures used in animal studies were
approved by the Committee on Animal Care at the Massachusetts Institute of
Technology and the La Jolla Institute for Allergy and Immunology Animal Care
Committee and were consistent with local, state, and federal regulations before
initiation of this research. Female C57BL/6 mice (8-10 wk old, Jackson Labora-
tories) were s.c. injected at the base of the tail with indicated doses of gp120 and
MPLA in 100 μL PBS at the specified doses and days. This injection location
drains to the inguinal lymph nodes, which were collected postmortem for
certain analyses. Alternatively, mice were injected intramuscularly with gp120
formulated in 100 μg Alum (Adju-Phos, Brenntag Biosector A/S).
For SOSIP trimer immunizations, 6- to 8-wk-old 129S1/SvImJ mice (Jackson
Laboratories) were used. Mice were given interscapular bolus immunizations
with 20 μg BG505 SOSIP.664 gp140 in 0.5 Units of ISCOMATRIX (CSL Ltd.). Os-
motic pumps containing 100 μg (2-wk slow release) or 50 μg (1-wk slow release)
BG505 SOSIP.664 gp140 in 0.5 Units of ISCOMATRIX were s.c. implanted in the
interscapular region. Blood (from retroorbital or submandibular; 100 μL) was
collected weekly into serum separator tubes (BD Corporation) and centrifuged
at 4,000 × g for 10 min at 4 °C. Alternatively, blood was collected in Eppendorf
tubes and centrifuged at 16,000 × g for 30 min at 4 °C. Sera extracted from
blood samples were stored at −80 °C until ready for analysis.
ELISA. Serum anti-gp120 IgG antibodies were quantified by endpoint ELISA
using gp120 as the capture antigen on 96-wellMaxisorpmicrotiter plates (Nunc).
Plates were incubated with 0.5 mg/mL poly-L-lysine in PBS for 4 h at room tem-
perature, blocked by 1% BSA in PBS overnight at 4 °C and incubated with 50 nM
gp120 in PBS with 1% BSA for 2 h at room temperature. Mouse sera was diluted
in PBS with 1% BSA at 1:3,000 or 1:30,000 and incubated for 1.5 h at 25 °C
followed by HRP-conjugated goat anti-mouse IgG (1:5,000 in PBS with 1% BSA)
for 1 h at 25 °C. Plates were washed four times in between each step with 0.05%
tween-20 in PBS. Plates were developed with TMB, stopped with 1M sulfuric
acid, and read at 450 and 570 nm using a Tecan M1000 plate reader. Anti-gp120
IgG antibody concentrations were calculated based on ELISA standards using
mb12, a monoclonal murine antibody from the NIH AIDS Reagent repository.
Analysis was done by subtracting the 570-nm signal from the 450-nm signal,
fitting the standard to a four-parameter log-logistic model with the drc package
in R, and using that fit to compute antibody concentrations.
Serum anti-BG505 SOSIP.664 gp140 IgG titers were quantified as previously
described (39). Briefly, 96-well MaxiSorp plates (Thermo Scientific) were coated
with 5 μg/mL D7324 (Aalto Bio Reagents Ltd.) overnight at 4 °C. After blocking
with 2% (wt/vol) skim milk, 0.3 μg/mL C terminus D7324-tagged BG505
SOSIP.664 trimers were added followed by mouse serum and HRP-labeled goat
anti-mouse IgG, Fcγ fragment specific (Jackson Immunoresearch) with washes in
between each step. For V3 specific ELISAs, plates were coated overnight at 4 °C
with 2 μg/mL BG505 V3 peptide (TRPNNNTRKSIRIGPGQAFYATG) in PBS. After
blocking, mouse serum was added followed by HRP-labeled goat anti-mouse
IgG with washes in between each step. Colorimetric detection was per-
formed using a TMB substrate kit (Thermo Scientific) and stopped with 2N
sulfuric acid. Absorbance was read at 450 nm. Endpoint titers were calcu-
lated in GraphPad Prism after subtracting the average background optical
density (OD) from all values measured at 450 nm.
Flow Cytometry Analysis of Lymph Nodes. Inguinal and brachial lymph nodes
were harvested and single-cell suspensions were obtained by passage of the
lymph nodes through a 70-μm filter (BD Biosciences). Cells were washed with
PBS and labeled with Live/Dead Aqua (Life Technologies) for 15 min at 25 °C.
For B-cell activation and germinal center analysis, samples were treated with
anti-CD16/32 (TruStain fcX; BioLegend), followed by staining with anti–CD3e-
PerCP-Cy5.5 (BD Biosciences), anti–B220-PE-Cy7 (eBioscience), anti-CD138-PE (BD
Biosciences), anti–IgD-APC (eBioscience), anti–GL7-FITC (BD Biosciences), anti-
MHCII-AF700 (BioLegend), anti–CD86-V450 (BD Biosciences), and PNA-biotin
(VectorLabs) + Streptavidin-APCeF780 (eBioscience). CXCR5 stains were per-
formed as previously described (59). Flow cytometry was carried out on a BD
LSR Fortessa or LSR II.
Histology of Lymph Nodes. Inguinal lymph nodes were harvested, embedded in
OCT compound, and frozen on dry ice. Frozen tissues were sectioned at 10-μm
thickness, fixed with 4% (vol/vol) paraformaldehyde in PBS, and stained with
biotinylated anti-B220 (BioXCell), Streptavidin-APC (BD Biosciences), anti–GL7-
FITC (BioLegend), and anti-FITC-AF488 (Jackson ImmunoResearch) for germinal
center visualization. Samples were imaged with a PerkinElmer Ultraview Spin-
ning Disk Confocal using a 40× oil objective with a Hammamatsu ORCA-ER
CCD camera.
Antigen Draining Experiments. Gp120 was labeled with IRDye 800CW-NHS
(LI-COR Biosciences) following the manufacturer’s instructions. Subsequently, mice
were vaccinated with labeled gp120 in the same manner as before according to
the dosing profiles in Fig. 4. Mice were killed, and their inguinal lymph nodes
were removed. The lymph nodes were digested, and fluorescence was measured
using a LI-COR Odyssey CLx Infrared Imaging System (LI-COR Biosciences). Alter-
natively, mice were vaccinatedwith intact Phycoerythrin (PE) protein andMPLA as
per the aforementioned exp-inc dosing profile or bolus injections and with 10 μg
of BV421 labeled anti-CD21/35 antibody (to label the follicular dendritic cells in
vivo) 48 h following the bolus or 48 h following the last exp-inc injection. Sixteen
hours after anti-CD21/35 injections, mice were killed, and lymph nodes were
extracted and processed to visualize the subnodal distribution of PE relative to
FDC in whole intact lymph nodes using the 3DISCO tissue-clearing method (60).
Briefly, lymph nodes were fixed in 4% (vol/vol) paraformaldehyde in PBS for 2 d,
washed and cleared using the DISCO solvents, and subsequently imaged using an
Olympus Fluoview FV1200microscope equippedwith 30× (NA 1.05) objective. The
images were then processed and reconstructed using Fiji image analysis software.
Z-stacks were acquired for individual FDC clusters. Maximum intensity projections
were prepared to show the distribution of antigen across the cluster.
Germinal Center Model Calculations. The computational model accounted for
antigen transport/clearance, the germinal center reaction, and antibody pro-
duction by plasma cells upon vaccinations. The model is expressed in terms of a
set of chemical reactions between species, including the four key reactions
detailed in Fig. 3B. Parameters used for the model were collected from the
literature and are listed in Table S2, with the exception of the plasma cell an-
tibody secretion rate k. This single parameter was fit to reproduce the five IgG
measurements made at days 7 and 14 from each dosing strategy. The confi-
dence interval of the best-fit parameter was 1.89 × 106 to 3.16 × 106. Mea-
surements before the boost injection at day 21 were chosen to fit the
parameter because the model does not include memory B cells and, thus, the
effect of their reactivation upon boost. Evolution of these reactions in time was
determined by computationally solving a set of partial differential equations
describing the temporal evolution of these reactions (Table S3) using Matlab;
the results were robust with respect to a range of initial conditions.
Statistical Analysis. Error bars are given as SEM of the log-transformed data.
Kruskal–Wallis test with Dunn’s post hoc test or two-way analysis of variance
(ANOVA) with Dunnett’s post hoc test were used to account for multiple com-
parisons in computing confidence intervals. P values were determined by unpaired
Mann–Whitney test. Data were plotted and analyzed with GraphPad Prism and R.
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